VWM
INDV icon

Vermillion Wealth Management’s Indivior Pharmaceuticals INDV Stock Holding History

Vermillion Wealth Management’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-8
Closed -$245 – 1973
2026
Q1 		$245 Buy
+8
New +$264 ﹤0.01% 1258

Other funds holding INDV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vermillion Wealth Management's INDV Position: Q2 2026 in Review

Vermillion Wealth Management sold out of Indivior Pharmaceuticals (INDV) in Q2 2026, closing a stake of 8 shares — an estimated $245 sold.

Vermillion Wealth Management first reported a position in INDV in Q1 2026 and held it in 1 quarter. The position peaked at $245 in Q1 2026. 336 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

  • Vermillion Wealth Management reported no remaining Indivior Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Vermillion Wealth Management sold 8 Indivior Pharmaceuticals shares in Q2 2026, an estimated $245.
  • Vermillion Wealth Management first reported a position in Indivior Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • Vermillion Wealth Management's Indivior Pharmaceuticals position peaked at $245 in Q1 2026.
  • 336 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on Vermillion Wealth Management's 13F filing for Q2 2026, filed 16 Jul 2026.